mmunogenicity of protein drugs is a major issue and in recent years it became clear that aggregation plays an important role in
initiating an adverse immune response. Since then new analytical tools have been implemented in drug development processes
to detect and characterize drug aggregates. Besides analytical tools, industry uses biological tools such as in silico, in vitro and in
vivo to predict immunogenicity of protein drugs. This presentation gives an overview about why aggregates are immunogenic, how
they trigger the immune response, how we can measure aggregates and their impact on the immune system and new methods on
how to prevent aggregation.
Sauerborn spent most of her undergrad years in well-known institutes such as the Centers for Disease Control and Prevention in Atlanta to widen
her knowledge in immunology. After acquiring her Masters in Science she joined the lab of Prof. Schellekens and Prof. Jiskoot, two experts in
immunogenicity of protein drugs, to shed more light on the immunological aspects of antibody formation against aggregated protein therapeutics.
After obtaining her PhD she started a spin-off, ADA InVivo BV, a biotech CRO in the field of drug safety. Currently she is a project leader at the
bioanalysis and immunogenicity department at TNO Triskelion BV, a Dutch CRO.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals